NCT02398240View on ClinicalTrials.gov

Brentuximab for Newly Diagnosed Hodgkin Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

May 31, 2015

Primary Completion Date

June 30, 2022

Study Completion Date

December 31, 2022

Conditions
Hodgkin Lymphoma
Interventions
DRUG

Brentuximab Vedotin

Day 1 and 15 Dose: 1.2 mg/kg/dose. (Maximum dose is 120 mg)

DRUG

Doxorubicin

Days: 1 and 15 Dose: 25 mg/m2/dose.

DRUG

Vincristine

Days: 1 and 15 Dose: 1.5 mg/m2/dose (max: 2 mg/dose).

DRUG

Rituximab

Days: 2 and 16 Dose: 375 mg/m2/dose.

Trial Locations (1)

10595

New York Medical College, Valhalla

All Listed Sponsors
lead

Mitchell Cairo

OTHER

NCT02398240 - Brentuximab for Newly Diagnosed Hodgkin Disease | Biotech Hunter | Biotech Hunter